<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20100414003706N39</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-08-23</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of epidural analgesia and aromatherapy with lavender regarding fear of childbirth</public_title>
      <acronym></acronym>
      <scientific_title>Fear of childbirth in epidural analgesia and aromatherapy with lavender: a randomized two-arm parallel-group trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-09-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>56</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/57640</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Participants will be individually randomized into intervention or control groups using stratified (previous history of labor and type of labor onset (spontaneous or induction)) block randomization with block size of four and six. Allocation sequence will be determined using a computerized program (www.random.org). Sequentially numbered opaque sealed envelopes will be used to conceal the  allocation. Allocation sequence and the envelopes will be prepared by a person not involved in participant recruitment and allocation, or data collection.</study_design>
      <phase>3</phase>
      <hc_freetext>Fear during and after childbirth.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: In the epidural group, the injection will be performed by an anesthesiologist according to the national protocol for painless delivery, and with the intermittent injection technique. In this technique, depending on the patient's needs and pain, 5 to10 milliliter of bupivacaine 0.125 to 0.625% or rupivacaine 0.1 to 0.2% will be repeated every 30 to 60 minutes. Intervention 2: Intervention group 2: In the aromatherapy group, a piece of linen cloth (with length and width about 15 centemeter), impregnated with 0.1 milliliter of lavender essential oil prepared by Barij Essential Oil Company, diluted with 1 milliliter of distilled water, is placed on the patient's neck. Linen fabric is used to preserve the scent and the skin does not absorb the essential oil and prevent complications. Fabrics will be stored in sterile conditions.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Requested data will be provided to researchers for statistical analysis (meta- analysis) of the submitted proposal.

When:
starting immediately after publication of the study results

To whom:
Data will be available to researchers working at academic organizations, as well as to chief editor (and reviewers) of the journal of the submitted manuscript/s, if requested.

Conditions:
The data will be available to researchers upon request and submission of a proposal to perform meta-analysis using IPD data after being unidentified. Also, in exceptional cases, data will be made available to journal of submitted manuscript/s for checking accuracy of the dat

Where to obtain:
Refer to the email address (alizades@tbzmed.ac.ir; mhammadalizadehs@gmail.com)

How to obtain:
The requests will be sent by email and data will be available within a week.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zohreh Zakavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nursing &amp; Midwifery Faculty, South Shariati Ave., Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>59691-15868</zip>
        <telephone>+98 44 4436 3557</telephone>
        <email>zohreh.zakavi.92@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sakineh Mohammad-Alizadeh-Charandabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Nursing &amp; Midwifery, South Shariati Ave., Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5138947977</zip>
        <telephone>+98 41 3479 6969</telephone>
        <email>alizades@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Have a healthy sense of smell
Age 18 to 45 years
First to third childbirth
Live single fetus with cephalic presentation
Gestational age 37 to 41 weeks
regular labor contractions
Cervical dilatation 4 to 5 cm
No received sedation in 4 hours prior to intervention
Having a low-risk pregnancy (absence of third trimester bleeding, placental abruption, placenta previa, fetal growth disorder, etc.)</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Any surgery on the uterus including cesarean section
Any contraindications to vaginal delivery including Cephalopelvic disproportion (CPD)
Abnormal amniotic fluid volume
Any contraindications to receive epidural analgesia or aromatherapy, including a history of allergies to herbal or analgesic drugs
Pregnancy with the help of assisted reproductive techniques (ART)
Any major physical or mental illness
Severe obesity (Body mass index (BMI) higher than 35 kilograms per square meter)
Unwillingness to participate in the study or the inability to obtain informed consent from the person, including having excessive anxiety or stress
Non-reactive fetal heart rate</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F40.232</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Fear of other medical care</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: In the epidural group, the injection will be performed by an anesthesiologist according to the national protocol for painless delivery, and with the intermittent injection technique. In this technique, depending on the patient's needs and pain, 5 to10 milliliter of bupivacaine 0.125 to 0.625% or rupivacaine 0.1 to 0.2% will be repeated every 30 to 60 minutes.</i_keyword>
      <i_keyword>Intervention group 2: In the aromatherapy group, a piece of linen cloth (with length and width about 15 centemeter), impregnated with 0.1 milliliter of lavender essential oil prepared by Barij Essential Oil Company, diluted with 1 milliliter of distilled water, is placed on the patient's neck. Linen fabric is used to preserve the scent and the skin does not absorb the essential oil and prevent complications. Fabrics will be stored in sterile conditions.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Childbirth  fear. Timepoint: One and two hours after intervention. Method of measurement: Delivery Fear Scale.</prim_outcome>
      <prim_outcome>Severity of postpartum fear. Timepoint: Two hours and 5 weeks after delivery. Method of measurement: Wijma Version B scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Pain intensity. Timepoint: At 4 to 5 cm cervical dilatation (just before intervention), 30 minutes after the intervention and then every hour until delivery. Method of measurement: Visual analog scale.</sec_outcome>
      <sec_outcome>Childbirth experience satisfaction. Timepoint: 12 to 24 hours after delivery. Method of measurement: Birth satisfaction scale-revised questionnaire.</sec_outcome>
      <sec_outcome>Duration of the first, second and third stages of labor and intervention until delivery. Timepoint: beginning to the end of intervention. Method of measurement: Partograph.</sec_outcome>
      <sec_outcome>Emergency cesarean section. Timepoint: beginning to the end of intervention. Method of measurement: Researcher observation.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-08-02</approval_date>
        <contact_name>Ethics committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>No. 2 Central Building, Tabriz University of Medical Sciences, Golgasht Ave., Tabriz, Iran Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
